Articles published by ImmunityBio

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

February 02, 2026

From ImmunityBio

Via Business Wire

Tickers IBRX

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

January 14, 2026

From ImmunityBio

Via Business Wire

Tickers IBRX

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

December 12, 2025

From ImmunityBio

Via Business Wire

Tickers IBRX

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

March 06, 2024

From ImmunityBio

Via Business Wire

Tickers IBRX

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

March 05, 2024

From ImmunityBio

Via Business Wire

Tickers IBRX

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

February 21, 2024

From ImmunityBio

Via Business Wire

Tickers IBRX

NEJM Evidence Publishes Results for ImmunityBio’s QUILT 3.032 Registrational Trial of IL-15 Superagonist N-803 Plus BCG in Patients with Bladder Cancer

November 10, 2022

From ImmunityBio

Via Business Wire

Tickers IBRX

ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ

July 28, 2022

From ImmunityBio

Via Business Wire

Tickers IBRX

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.